Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study

Journal of the American College of Cardiology

Volumn 36, Issue 5, 2000, Pages 1529-1535

  Takagi, Tsutomu ^a   Akasaka, Takashi ^a   Yamamuro, Atsushi ^a   Honda, Yasuhiro ^a   Hozumi, Takeshi ^a   Morioka, Shigefumi ^a   Yoshida, Kiyoshi ^b  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TROGLITAZONE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INTIMA; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CELL DIVISION; CHROMANS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; STENTS; THIAZOLES; THIAZOLIDINEDIONES; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0034332862     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00895-0     Document Type: Article

References (41)

1. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
2. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus
3. Three-year clinical follow-up after Palmaz-Schatz stenting
4. Predictive factors of restenosis after coronary stent placement
5. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study
6. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
7. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells
8. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
9. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes
10. Definition, diagnosis, and classification: Diabetes mellitus
11. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
12. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents
13. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin
14. Lesion-to-lesion independence of restenosis after treatment by conventional angioplasty, stenting, or directional atherectomy. Validation of lesion-based restenosis analysis
15. Patterns and mechanisms of in-stent restenosis. A serial intravascular study
16. Potential mechanisms promoting restenosis in diabetic patients
17. Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: Association with overexpression of PDGF beta-receptors
18. Insulin-like growth factors-I and platelet-derived growth factor-BB induces directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation
19. Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF beta-receptor overexpression of aortic media
20. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?
21. Insulin and atheroma: 20-y perspective
22. Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells
23. Insulin regulation of IGF-I expression in rat aorta
24. Metabolic effects of new oral hypoglycemic agents CS-045 in NIDM subjects
25. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
26. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
27. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells
28. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells
29. Increased intimal hyperplasia in patients with impaired glucose tolerance after coronary stent implantation: A serial intravascular ultrasound study
30. Increased intimal hyperplasia after coronary stent implantation in patients with hyperinsulinemia: A serial intravascular ultrasound study
31. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
32. Hepatic dysfunction associated with troglitazone
33. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone
34. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
35. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
36. Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis
37. Luminal loss and site of restenosis after Palmaz-Schatz coronary stent implantation
38. Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes
39. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
40. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation
41. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy